Patents by Inventor Merav Bassan
Merav Bassan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240041855Abstract: The subject invention provides a modified release solid oral dosage form comprising a therapeutically effective amount of Pridopidine or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable rate controlling excipient, wherein the solid oral dosage form provides an in vivo plasma pridopidine concentration profile having a Mean Cmax of about 1,400 ng/ml or less. The subject invention also provides a method of treating an individual afflicted with a neurodegenerative disease or disease related to dopamine, comprising once daily administration of a modified release solid oral dosage form.Type: ApplicationFiled: October 23, 2023Publication date: February 8, 2024Applicant: Prilenia Neurotherapeutics Ltd.Inventors: Daniella LICHT, Ioana Lovinger, Laura Yehudit Guilatt, Merav Bassan
-
Patent number: 11471449Abstract: This invention provides a method of improving cognitive function in a subject comprising periodically administering to the subject an amount of pridopidine or a pharmaceutically acceptable salt thereof effective to improve a cognitive function in the subject. The invention also provides a method of treating a subject afflicted with Alzheimer's disease, comprising periodically administering to the subject a pharmaceutical composition comprising an amount of pridopidine or a pharmaceutically acceptable salt thereof effective to treat the subject.Type: GrantFiled: October 3, 2019Date of Patent: October 18, 2022Assignees: Prilenia Neurotherapeutics Ltd., The Board of Regents of the University of Texas SystemInventors: Michal Geva, Ilya Bezprozvanny, Merav Bassan, Michael Hayden
-
Publication number: 20210308115Abstract: A method of treating a human patient afflicted with Huntington's disease, comprising periodically orally administering to the patient a pharmaceutical composition comprising pridopidine, its analog or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: June 20, 2021Publication date: October 7, 2021Applicant: PRILENIA NEUROTHERAPEUTICS LTD.Inventors: Merav Bassan, Esther Lukasiewicz Hagai, Eli Eyal, Anna Kristina Sveinsdotter Teige Wickenberg
-
Patent number: 11090297Abstract: A method of treating a human patient afflicted with Huntington's disease, comprising periodically orally administering to the patient a pharmaceutical composition comprising pridopidine, its analog or a pharmaceutically acceptable salt thereof.Type: GrantFiled: June 12, 2019Date of Patent: August 17, 2021Assignee: PRILENIA NEUROTHERAPEUTICS LTD.Inventors: Merav Bassan, Esther Lukasiewicz Hagai, Eli Eyal, Anna Kristina Sveinsdotter Teige Wickenberg
-
Patent number: 10603311Abstract: This invention provides a method of improving cognitive function in a subject comprising periodically administering to the subject an amount of pridopidine or a pharmaceutically acceptable salt thereof effective to improve a cognitive function in the subject. The invention also provides a method of treating a subject afflicted with Alzheimer's disease, comprising periodically administering to the subject a pharmaceutical composition comprising an amount of pridopidine or a pharmaceutically acceptable salt thereof effective to treat the subject.Type: GrantFiled: February 24, 2016Date of Patent: March 31, 2020Assignees: PRILENIA NEUROTHERAPEUTICS LTD., THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEMInventors: Michal Geva, Ilya Bezprozvanny, Merav Bassan, Michael Hayden
-
Publication number: 20200093813Abstract: This invention provides a method of improving cognitive function in a subject comprising periodically administering to the subject an amount of pridopidine or a pharmaceutically acceptable salt thereof effective to improve a cognitive function in the subject. The invention also provides a method of treating a subject afflicted with Alzheimer's disease, comprising periodically administering to the subject a pharmaceutical composition comprising an amount of pridopidine or a pharmaceutically acceptable salt thereof effective to treat the subject.Type: ApplicationFiled: October 3, 2019Publication date: March 26, 2020Applicants: PRILENIA NEUROTHERAPEUTICS LTD., THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEMInventors: Michal Geva, Ilya Bezprozvanny, Merav Bassan, Michael Hayden
-
Publication number: 20190350915Abstract: A method of treating a human patient afflicted with Huntington's disease, comprising periodically orally administering to the patient a pharmaceutical composition comprising pridopidine, its analog or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: June 12, 2019Publication date: November 21, 2019Applicant: PRILENIA NEUROTHERAPEUTICS LTD.Inventors: Merav BASSAN, Esther Lukasiewicz Hagai, Eli Eyal, Anna Kristina Sveinsdotter Teige Wickenberg
-
Publication number: 20190209542Abstract: The subject invention provides a modified release solid oral dosage form comprising a therapeutically effective amount of Pridopidine or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable rate controlling excipient, wherein the solid oral dosage form provides an in vivo plasma pridopidine concentration profile having a Mean Cmax of about 1,400 ng/ml or less. The subject invention also provides a method of treating an individual afflicted with a neurodegenerative disease or disease related to dopamine, comprising once daily administration of a modified release solid oral dosage form.Type: ApplicationFiled: August 28, 2018Publication date: July 11, 2019Applicant: PRILENIA THERAPEUTICS DEVELOPMENT LTD.Inventors: Daniella Licht, Ioana Lovinger, Laura Yehudit Guilatt, Merav Bassan
-
Patent number: 10322119Abstract: A method of treating a human patient afflicted with Huntington's disease, comprising periodically orally administering to the patient a pharmaceutical composition comprising pridopidine or a pharmaceutically acceptable salt thereof such that greater than 90 mg of pridopidine is administered to the patient per day.Type: GrantFiled: June 19, 2014Date of Patent: June 18, 2019Assignee: PRILENIA THERAPEUTICS DEVELOPMENT LTD.Inventors: Merav Bassan, Esther Lukasiweicz Hagai, Eli Eyal, Anna Kristina Sveinsdotter Teige Wickenberg
-
Publication number: 20160243098Abstract: This invention provides a method of improving cognitive function in a subject comprising periodically administering to the subject an amount of pridopidine or a pharmaceutically acceptable salt thereof effective to improve a cognitive function in the subject. The invention also provides a method of treating a subject afflicted with Alzheimer's disease, comprising periodically administering to the subject a pharmaceutical composition comprising an amount of pridopidine or a pharmaceutically acceptable salt thereof effective to treat the subject.Type: ApplicationFiled: February 24, 2016Publication date: August 25, 2016Applicants: Teva Pharmaceuticals International GmbH, The Board of Regents of The University of Texas SystemInventors: Michal Geva, Ilya Bezprozvanny, Merav Bassan, Michael Hayden
-
Publication number: 20150202302Abstract: The subject invention provides a modified release solid oral dosage form comprising a therapeutically effective amount of Pridopidine or as pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable rate controlling excipient, wherein the solid oral dosage form provides an in vivo plasma pridopidine concentration profile having a Mean Cmax of about 1,400 ng/ml or less. The subject invention also provides a method of treating an individual afflicted with a neurodegenerative disease or disease related to dopamine, comprising once daily administration of a modified release said oral dosage form.Type: ApplicationFiled: January 21, 2015Publication date: July 23, 2015Applicant: IVAX INTERNATIONAL GMBHInventors: Daniella Licht, Ioana Lovinger, Laura Yehudit Guilatt, Merav Bassan
-
Publication number: 20140378508Abstract: A method of treating a human patient afflicted with Huntington's disease, comprising periodically orally administering to the patient a pharmaceutical composition comprising pridopidine or a pharmaceutically acceptable salt thereof such that greater than 90 mg of pridopidine is administered to the patient per day.Type: ApplicationFiled: June 19, 2014Publication date: December 25, 2014Applicant: IVAX INTERNATIONAL GMBHInventors: Merav Bassan, Esther Lukasiewicz Hagai, Eli Eyal, Anna Kristina Sveinsdotter Teige Wickenberg
-
Publication number: 20140162954Abstract: The present invention provides a method of treating a human patient in need of growth hormone therapy by periodically administering to the human patient for more than two weeks an effective amount of a composition comprising a pharmaceutically acceptable carrier and a fusion protein whose amino acid sequence is set forth as SEQ ID NO:1, so as to thereby treat the human patient. The present invention also provides a method of treating a human patient in need of growth hormone therapy by administering to the human patient, in a clinically effective regimen, a clinically effective dose of a composition comprising a pharmaceutically acceptable carrier and a fusion protein whose amino acid sequence is set forth as SEQ ID NO:1, wherein the clinically effective dose and clinically effective regimen are selected by a series of steps.Type: ApplicationFiled: December 10, 2013Publication date: June 12, 2014Applicant: TEVA PHARMACEUTICAL INDUSTRIES, LTDInventors: Kurt Brown, Merav Bassan
-
Patent number: 7863247Abstract: The invention relates to methods for reducing a condition associated with fetal alcohol syndrome in a subject who is exposed to alcohol in utero with an ADNF polypeptide (e.g, ADNF I polypeptides, ADNF III polypeptides, or mixtures of ADNF I and ADNF III polypeptides). In one embodiment, the present invention relates to methods for reducing a condition associated with fetal alcohol syndrome in a subject who is exposed to alcohol in utero with a mixture of ADNF I and ADNF III polypeptides. The present invention further relates to methods for reducing neuronal cell death by contacting neuronal cells with a mixture of ADNF I and ADNF III polypeptides. Still further, the present invention relates to a pharmaceutical composition comprising a mixture of ADNF I and ADNF III polypeptides.Type: GrantFiled: March 10, 2000Date of Patent: January 4, 2011Assignee: Ramot-University Authority for Applied Research and Development Ltd.Inventors: Douglas E. Brenneman, Catherine Y. Spong, Illana Gozes, Merav Bassan, Rachel Zamostiano
-
Publication number: 20090258863Abstract: A method of treating a human patient afflicted with amyotrophic lateral sclerosis (ALS) comprising periodically administering to the human patient for a therapeutically effective duration a pharmaceutical composition comprising an amount of talampanel therapeutically effective to provide a benefit to the human patient, thereby treating the human patient.Type: ApplicationFiled: April 10, 2009Publication date: October 15, 2009Inventors: Miri Ben-Ami, Merav Bassan, Ella Sorani
-
Publication number: 20090124543Abstract: The present invention relates generally to Activity Dependent Neurotrophic Factor III (ADNF III), also known as Activity Dependent Neuroprotective Protein (ADNP). More particularly, the present invention relates to nucleic acid sequences encoding ADNF III polypeptides; ADNF III polypeptides encoded by such nucleic acid sequences; antibodies to ADNF III polypeptides; and methods of using such ADNF III polypeptides for the treatment of neurological deficiencies and for the prevention of cell death associated with (1) gp120, the envelope protein from HIV; (2) N-methyl-D-aspartic acid (excito-toxicity); (3) tetrodotoxin (blockage of electrical activity); and (4) ?-amyloid peptide, a substance related to neuronal degeneration in Alzheimer's disease.Type: ApplicationFiled: August 13, 2007Publication date: May 14, 2009Applicants: The Govt. of the U.S.A., as represented by the Secretary of the Dept. of Health & Human Services, Ramot at Tel-Aviv University Ltd.Inventors: Illana Gozes, Douglas E. Brenneman, Merav Bassan, Rachel Zamostiano
-
Patent number: 7264947Abstract: The present invention relates generally to Activity Dependent Neurotrophic Factor III (ADNF III), also known as Activity Dependent Neuroprotective Protein (ADNP). More particularly, the present invention relates to nucleic acid sequences encoding ADNF III polypeptides; ADNF III polypeptides encoded by such nucleic acid sequences; antibodies to ADNF III polypeptides; and methods of using such ADNF III polypeptides for the treatment of neurological deficiencies and for the prevention of cell death associated with (1) gp120, the envelope protein from HIV; (2) N-methyl-D-aspartic acid (excito-toxicity); (3) tetrodotoxin (blockage of electrical activity); and (4) ?-amyloid peptide, a substance related to neuronal degeneration in Alzheimer's disease.Type: GrantFiled: July 17, 2003Date of Patent: September 4, 2007Assignee: United States of America, as represented by the Secretary of the Department of Health and Human ServicesInventors: Illana Gozes, Douglas E. Brenneman, Merav Bassan, Rachel Zamostiano
-
Patent number: 6933277Abstract: This invention relates to a method for reducing a condition associated with fetal alcohol syndrome in a subject who is exposed to alcohol in utero with an ADNF polypeptide. In particular, the present invention relates to a method of reducing a condition associated with fetal alcohol syndrome in a subject who is exposed to alcohol in utero with a combination of ADNF I and ADNF III polypeptides. The present invention further relates to a method for reducing neuronal cell death by contacting neuronal cells with a combination of ADNF I and ADNF III polypeptides. Still further, the present invention relates to a pharmaceutical composition comprising a combination of ADNF I and ADNF III polypeptides.Type: GrantFiled: March 12, 1999Date of Patent: August 23, 2005Assignees: The United States of America as represented by the Department of Health and Human Services, Ramot University Authority for Applied Research and Industrial Development, Ltd.Inventors: Douglas E. Brenneman, Catherine Y. Spong, Illana Gozes, Merav Bassan, Rachel Zamostiano
-
Publication number: 20040053313Abstract: The present invention relates generally to Activity Dependent Neurotrophic Factor III (ADNF III), also known as Activity Dependent Neuroprotective Protein (ADNP). More particularly, the present invention relates to nucleic acid sequences encoding ADNF III polypeptides; ADNF III polypeptides encoded by such nucleic acid sequences; antibodies to ADNF III polypeptides; and methods of using such ADNF III polypeptides for the treatment of neurological deficiencies and for the prevention of cell death associated with (1) gp120, the envelope protein from HIV; (2) N-methyl-D-aspartic acid (excito-toxicity); (3) tetrodotoxin (blockage of electrical activity); and (4) &bgr;-amyloid peptide, a substance related to neuronal degeneration in Alzheimer's disease.Type: ApplicationFiled: July 17, 2003Publication date: March 18, 2004Applicants: The Government of the USA as Represented by the Secretary of the Dept. of Health & Human Services, Ramot University Authority for Applied Research and Industrial Development, Ltd.Inventors: Illana Gozes, Douglas E. Brenneman, Merav Bassan, Rachel Zamostiano
-
Patent number: 6649411Abstract: The present invention provides methods of using antisense ADNF III oligonucleotides to inhibit the growth of pathologically proliferating cells. The invention also provides methods and kits for using ADNF III nucleic acid probes to detect the presence of pathologically proliferating cells in human tissues.Type: GrantFiled: July 30, 1999Date of Patent: November 18, 2003Assignees: The United States of America as represented by the Department of Health and Human Services, Ramot at Tel-Aviv University Ltd.Inventors: Illana Gozes, Douglas E. Brenneman, Rachel Zamostiano, Edgar Gelber, Albert Pinhasov, Merav Bassan